CSCharles A. Staley

Charles A. Staley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles A. Staley has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).

    by Nabil F. Saba, Seth D Force, Charles A. Staley, Felix G Fernandez, Field F. Willingham, Pickens Allan, Kenneth Cardona, Zhengjia Chen, Dana Backlund Cardin, Eric Lambright, et al.

    E15607 Background: Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation and platinum agents in EC. We conducted a multi-institutional phase IB trial to determine the recommended phase II dose (RP2D) of concurrent everolimus with carboplatin and radiation in non-metastatic EC pts. Methods: Patients with untreated, localized EC and ECOG performance status 0-1 were eligible. Following two cycles of induction Capecitabine/Oxaliplatin (XELOX), pts without evidence of disease progression, received concurrent chemoradiation (total dose: 50.4Gy in 28 fractions), weekly carboplatin (AUC = 2), and escalating doses of everolimus. A standard 3+3 dose escalation design was used. Results: Nineteen patients were enrolled. There were two screen failures (thrombocytopenia, metastases) and 4 pts were removed due to poor tolerance of XELOX (2 pts) or disease progression (2 pts). A total of 13 pts with stage II/III (6/7) EC completed concurrent therapy. Median age 58 (44-71yrs), 85% males; all had adenocarcinoma deemed resectable. One pt at dose level 1 (2.5 mg/QOD), was replaced due to ongoing anxiety. One of 6 pts had a DLT (bowel ischemia). At dose level 2 (2.5mg/QD), 2 out of 6 patients had a DLT (fever with neutropenia and nausea). The RP2D of everolimus was 2.5 mg QOD. Clinically relevant ≥ grade 3 toxicities included lymphopenia (25%), dehydration (12%), fatigue, leukopenia, hyponatremia, abdominal pain, vomiting (each 6%). R0 resection was achieved in 100%; a pathologic response rate (RR) of 40% and a pathologic complete response (pCR) rate of 23% were observed. The 2-year PFS and OS were 50% and 49.6% respectively. Conclusions: The RP2D of everolimus with concurrent weekly carboplatin and radiation is 2.5 mg QOD. Despite the 100% R0 resection rate, the pCR and OS rates were within the expected historical controls. (The study was funded by Novartis Pharmaceuticals) Clinical trial information: NCT01490749.

  • HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for novel therapeutic targets.

    by Cecilia Grace Ethun, Lauren McLendon Postlewait, Alexandra Grace Lopez-Aguiar, Kristen Zhelnin, Alyssa Krasinskas, Bassel F. El-Rayes, Maria C. Russell, David A. Kooby, Charles A. Staley, Kenneth Cardona, et al.

    235 Background: Heat shock protein (HSP) 90 promotes tumor growth and is overexpressed in many malignancies. HSP90 expression profile and its potential as a therapeutic target in primary and metastatic neuroendocrine tumors (NETs) are not known. Methods: HSP90 cytoplasmic expression and Ki-67 index were re-reviewed and scored by a pathologist blinded to all other clinicopathologic variables using tissue microarray (TMA) blocks created in triplicate for patients who underwent resection of primary and metastatic gastroenteropancreatic (GEP) neuroendocrine tumors at a single institution from 2000-2013. Primary outcome was recurrence-free survival (RFS). Results: Of 278 tumors reviewed, 194 (68%) were primary GEP NETs, and 31 (11%) were NET liver metastases. Of the primary GEP NETs, mean age was 56yrs, 42% were male; 103 (53%) were pancreas and 44 (23%) were small bowel. HSP90 expression was high in 66 (34%) and low in 128 (66%). Compared to low expression, high HSP90 was associated with lymphovascular invasion (70vs42%; p = 0.049) and advanced T-stage (T3/T4: 48vs27%; p = 0.01). Among patients who underwent curative-intent resections for primary, non-metastatic NETs (n = 147), high HSP90 was associated with decreased 1-, 3-, and 5-yr RFS (80%, 72%, 62%) compared to low (89%, 86%, 83%; p = 0.03), which persisted on multivariable analysis (HR 5.2, 95%CI 1.7-16.0; p = 0.004), after accounting for positive margin, LN involvement, increased tumor size, site of primary tumor, and Ki-67 index. When assessing NET liver metastases, high HSP90 expression was seen in 4 (13%) patients and low in 27 (87%). Similar to primary GEP NETs, patients with liver metastases that exhibited high HSP90 expression had decreased 1-, 3-, and 5-yr progression-free survival (25%, 25%, 0%) compared to those with low HSP90 (69%, 49%, 33%; p = 0.052). Conclusions: Heat shock protein 90 exhibits differential expression in resected GEP NETs and liver metastases. High cytoplasmic expression is associated with early recurrence of disease, even after accounting for other adverse pathologic factors, including Ki-67 index. HSP90 inhibition is a potential target for novel therapeutic strategies for neuroendocrine tumors.


  • Post-hepatectomy hyperbilirubinemia: The point of no return

    by Jessica Y. Liu, Lauren M. Postlewait, Joanna W. Etra, Malcolm H. Squires, Kenneth Cardona, Joshua H. Winer, Juan M. Sarmiento, Charles A. Staley, Shishir K. Maithel, David A. Kooby, et al.


  • Despite Guidelines, Preoperative Administration of Subcutaneous Heparin for Venous Thromboembolism Prophylaxis Is Severely Underutilized

    by Seyed Amirhossein Razavi, Toncred M. Styblo, Juan M. Sarmiento, David A. Kooby, Patrick S. Sullivan, Shishir Maithel, Virginia L. Shaffer, Charles A. Staley, Keith A. Delman


  • Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years

    by Gillian G. Baptiste Ba, Lauren M. Postlewait, Cecilia G. Ethun, Nina Le, Mia R. McInnis, Maria C. Russell, Joshua H. Winer, David A. Kooby, Charles A. Staley, Shishir K. Maithel, et al.

    Background and Objectives The prognostic implication of symptomatic presentation of gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) remains unclear. Methods Patients who underwent resection of nonfunctional GEP‐NETs (2000–2014) were analyzed. Primary outcomes were overall survival (OS) and distant recurrence‐free survival (RFS). Results Symptomatic presentation was seen in 208 (61%) of 339 patients and was associated with younger age (55 vs. 59 yrs, P = 0.001), higher tumor grade (38% vs. 21%, P = 0.027), presence of lymphovascular invasion (58% vs. 33%, P < 0.001), presence of perineural invasion (54% vs. 29%, P = 0.002), and advanced disease (T3/T4/N1/M1 [63% vs. 44%, P = 0.002]), but not tumor size (2.6 vs. 2.5 cm, P = 0.74). Symptomatic presentation was associated with decreased 3‐yr distant‐RFS (80% vs. 89%, P = 0.012), but not OS. When accounting for adverse features, symptomatic presentation remained independently associated with reduced distant‐RFS (HR 3.51, P = 0.007). On subgroup‐analysis of advanced disease patients, symptomatology was associated with reduced 3‐yr distant‐RFS (67% vs. 79%, P = 0.012) and persisted as an independent risk‐factor for decreased distant‐RFS (HR 3.01, P = 0.027). Conclusions Symptomatic presentation of GEP‐NETs is associated with aggressive features and worse distant‐RFS. Trials assessing adjuvant therapy for advanced GEP‐NETs are needed, and symptomatic presentation may be considered as one inclusion criterion. Following resection, symptomatic presentation should be taken into account when planning surveillance. J. Surg. Oncol. 2016;114:163–169.


  • Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.

    by Gillian G. Baptiste, Lauren McLendon Postlewait, Cecilia G. Ethun, Nina Le, Mia R. McInnis, Maria C. Russell, Joshua H. Winer, David A. Kooby, Charles A. Staley, Shishir Kumar Maithel, et al.

    228 Background: The prognostic implications on outcomes of symptomatic presentation of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) remains unclear. Methods: Patients who underwent curative-intent resection of nonfunctional, well-differentiated GEP NETs from 2000-2014 at a single institution were analyzed. Patients were classified as symptomatic if clinical symptoms were present at diagnosis. Primary end points were distant recurrence-free survival (DRFS) and overall survival (OS). Results: A total of 339pts were identified, of which 208pts (61%) were symptomatic at presentation. Symptomatic presentation was associated with younger age at presentation (55vs59yrs, p = 0.001), higher tumor grade (38vs21%, p = 0.027), LVI (58vs33%, p < 0.001), PNI (53vs30%, p = 0.002), and advanced disease (T3/T4/N1/M1 63vs44%, p = 0.002), but not tumor size (2.6vs2.5cm, p = 0.74). Symptomatic presentation was associated with decreased DRFS but not OS. When accounting for race, tumor size, positive resection margins, presence of metastatic disease, and positive lymph nodes on multivariate analysis (MVA), symptomatic presentation remained independently associated with reduced DRFS (HR 3.51, p = 0.007). On subgroup analysis of patients only with advanced disease (T3/T4/N1/M1), symptomatic presentation was still associated with decreased 3-yr DRFS (67vs79%, p = 0.012), but not OS. On MVA, symptomatic presentation persisted as an independent factor associated with decreased DRFS in patients with advanced disease (HR 2.89, p = 0.014). Conclusions: Symptomatic presentation of GEP NETs is associated with more aggressive pathologic features and worse DRFS than incidentally diagnosed NETs irrespective of tumor size. As our armamentarium of therapeutic agents for NETs expands and improves, trials assessing the value of adjuvant therapy for advanced GEP NETs are needed, and symptomatic presentation may be considered as one inclusion criterion. Following resection, symptomatic presentation should be taken into account when planning follow-up strategies, as these patients may require closer surveillance than their incidentally diagnosed counterparts.

  • A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial.

    by Lauren McLendon Postlewait, Cecilia G. Ethun, David A. Kooby, Juan Sarmiento, Charles A. Staley, Edith Brutcher, Volkan Adsay, Bassel F. El-Rayes, Shishir Kumar Maithel

    230 Background: Standard adjuvant treatment for resected pancreatic adenocarcinoma is gemcitabine (Gem) (CONKO-001 trial: Gem vs placebo DFS 13.4 vs 6.7 mo; p2) / Cis (50 mg/m2) Day 1/8/15, Q28d for 6 cycles. After enrolling 5 pts, this was modified to Day 1/15 due to toxicity. Two dose reductions were permitted. Intent to treat analyses were conducted. Tumor ERCC1 expression was evaluated by immunohistochemistry and dichotomized into low and high expression groups. Primary outcomes were RFS and OS stratified by ERCC1 expression. Results: Of 22 pts, 16 (73%) had Stage IIB disease, 5 (23%) Stage IIA, and 1 (4%) Stage IA. Thirteen (59%) completed all 6 cycles of therapy, of whom 9 required dose reduction. Of the remaining 9 pts, 4 completed >68% of intended therapy. Grade 3 and 4 toxicity occurred in 13 pts (59%); neutropenia was most common (n=9;41%). Median follow-up was 37.5 mo. Median RFS was 16.7 mo, and OS was 35.5 mo. ERCC1 tumor expression data were available for 20 pts: 15 low (75%) and 5 high (25%). Low compared to high ERCC1 was not associated with improved RFS (12.4 vs 16.7 mo; p=0.68) or OS (Median not reached vs 21.6 mo; p=0.22). Conclusions: Adjuvant gemcitabine/cisplatin is tolerated by patients with resected pancreatic adenocarcinoma. RFS and OS for Gem/Cis appear promising compared to historic control. Tumor ERCC1 expression can be reliably evaluated, and low expression is present in the majority of patients. Further prospective trials evaluating Gem/Cis as an adjuvant regimen and ERCC-1 as a biomarker in resected pancreatic adenocarcinoma are warranted. Clinical trial information: NCT01188109.

  • Small bowel neuroendocrine tumors: A critical analysis of diagnostic work-up and operative approach.

    by Cecilia Grace Ethun, Lauren McLendon Postlewait, Gillian G. Baptiste, Nina Le, Mia R. McInnis, Kenneth Cardona, Maria C. Russell, David A. Kooby, Charles A. Staley, Shishir Kumar Maithel

    203 Background: Small bowel neuroendocrine tumors (SB-NET) are rare, and often small and multifocal. They are difficult to localize preoperatively and can be overlooked during operative exploration. The optimal work-up and operative approach is not known. Methods: Patients who underwent resection of SB-NET at a single institution from 2000-2014 were included. Primary aim was to describe the diagnostic work-up, pathologic characteristics, and compare minimally-invasive (MIS) to open resection. Results: 93pts underwent resection for SB-NET. Median age was 61yrs; 52% were male. On presentation, 71% of pts were symptomatic and underwent an average of 3 diagnostic tests prior to resection: 45% had octreoscans, which identified the region of primary disease in 85%; 11% had small bowel enteroscopy, with a 10% diagnostic yield; 19% had capsule endoscopy, which saw a lesion in 83%, but in only 21% was the correct number of tumors seen. The diagnostic yield of capsule was 28% overall, but 82% in pts presenting with GI bleeding. 79pts (85%) underwent curative-intent resections. Median tumor size was 1.8cm and multiple primary tumors were seen in 34pts(42%), of whom 50% had > 3 tumors. 37% had metastatic and 70% had LN positive disease. 27pts underwent MIS resections vs 66 open. MIS pts were younger (56vs61yrs;p0.035) and less likely to have obstructive symptoms (4vs24%;p = 0.19) and metastatic disease at resection (19vs44%;p = 0.038). Compared to open, the MIS group had smaller (1.7vs2.4cm;p = 0.03) and fewer tumors resected (2vs5;p = 0.049), but similar LN yield (13vs12;p = 0.7). In pts without metastases undergoing curative-intent resection, MIS approach was still associated with fewer tumors removed compared to open (1.5vs4;p = 0.034). Conclusions: Capsule endoscopy appears to be better than small bowel enteroscopy at identifying occult small bowel neuroendocrine tumors, particularly when pts present with bleeding, but still may underestimate tumor burden. While MIS may be appropriate in select patients, recognizing the limitations of preoperative evaluation is critical when selecting the operative approach for these tumors, as heightened operative vigilance is often required.

  • An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A seven-institution analysis of 837 patients from the U.S. Gastric Cancer Collaborative.

    by Gregory C. Dann, Malcolm Hart Squires, Lauren McLendon Postlewait, David A. Kooby, George A. Poultsides, Sharon M. Weber, Mark Bloomston, Ryan C. Fields, Timothy M. Pawlik, Konstantinos Ioannis Votanopoulos, et al.

    120 Background: A recent single institutional study demonstrated that jejunostomy feeding tubes (J-tubes) placed during resection of gastric adenocarcinoma (GAC) are associated with increased complications and no change in receipt of adjuvant therapy. Our aim was to validate these findings in a large multi-institutional cohort. Methods: All patients who underwent resection for GAC at 7 institutions participating in the U.S. Gastric Cancer Collaborative from 2000-2012 were identified. Patients with metastatic disease were excluded. Univariate and multivariate logistic regression were performed to assess the association of J-tubes with postoperative complications and receipt of adjuvant therapy. Subset analysis of patients who underwent total vs subtotal gastrectomy was also performed. Results: Of 965 patients, 837 were included for analysis, of whom 265 (32%) received a J-tube. Patients receiving J-tubes demonstrated greater incidence of preoperative weight loss, lower BMI, greater extent of resection, and more advanced TNM stage. J-tube placement was associated with increased infectious complications (36% vs 19%;p

  • The prognostic value of signet ring cell histology in resected gastric cancer.

    by Lauren McLendon Postlewait, Malcolm Hart Squires, David A. Kooby, George A. Poultsides, Sharon M. Weber, Mark Bloomston, Ryan C. Fields, Timothy M. Pawlik, Konstantinos Ioannis Votanopoulos, Carl Richard Schmidt, et al.

    128 Background: Conflicting data exist on the prognostic implication of signet ring cell (SRC) histology in gastric adenocarcinoma (GAC). Our aim was to assess the association of SRC with recurrence and survival in patients undergoing resection of GAC. Methods: All pts who underwent curative intent resection for GAC from 2000 to 2012 at 7 academic institutions comprising the US Gastric Cancer Collaborative were included. 30-day mortalities were excluded. Survival analyses included Kaplan Meier log rank and multivariate Cox regression. Primary endpoints were recurrence-free survival (RFS) and overall survival (OS). Stage-specific analysis was performed. Results: Of 965 pts, 768 met inclusion criteria. SRC was present in 39.5% and was associated with female gender (52.9% vs 38.6%; p